← All trials
NCT03742505
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 17, 2019
- Primary completion
- May 31, 2023
- Completion date
- Aug 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 766
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OttawaLead sponsor
- University of OttawaOverall official - principal investigator
- University of OttawaReponsible party - principal investigator
- Canadian Institutes of Health Research (CIHR)Collaborator
- Canadian Critical Care Trials GroupCollaborator
- EuroPharma, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.